Wisp PT-141 Nasal Spray Review: What $175 Buys, What Wisp Doesn't Publish, and the Approved Options to Check First

Disclosure: The Wisp link in this article is not an affiliate link and carries no tracking code. We earn no commission from clicks or purchases through it, and we earn nothing from Vyleesi or its manufacturer. This article contains no affiliate links.

Wisp PT-141 nasal spray starts at $175 and may appeal if needles are a non-negotiable barrier. But the publicly rendered product page does not state the concentration, milligrams per spray, bottle volume, or dose count, so its cost per use cannot be calculated. It is compounded and not FDA-approved.^[1]

Before you pay, check the life-stage fork. For eligible premenopausal women with acquired, generalized HSDD, Vyleesi is an FDA-approved injectable bremelanotide product; its manufacturer says most commercially insured patients pay $0 and patients without coverage can access a four-dose box for $99, subject to program terms.^[11] For women under 65 with acquired, generalized HSDD, the Addyi label now covers both premenopausal and postmenopausal women.^[12]

The central problem with Wisp's offer is simpler than the science: $175 has no publicly disclosed quantity attached to it. This review shows what is verified, what remains unknown, why the nasal route was abandoned by the molecule's developer as a first-line program, and the seven questions that make the purchase checkable before checkout.

This review is about wisp, Inc. at hellowisp.com — not Wisp Resort, the musician, or a wireless internet provider.

Best for you / not for you

Worth investigating if…	Start somewhere else if…
Needles are a real, non-negotiable barrier and you still want to discuss a prescription nasal option	You have not checked whether you qualify for the FDA-approved option for your life stage
You are willing to ask for the concentration, milligrams per spray, dose count, and pharmacy name in writing before paying	You want a standardized dose printed on an FDA-approved label
You understand that the $175 starting price cannot currently be converted into cost per use	You need a clear cost per dose before committing
You can accept a final-sale prescription purchase if it does not help	You are assuming there is a trial period or satisfaction guarantee
Low desire is the problem itself, not pain, dryness, a medication effect, uncontrolled sleep disruption, or a relationship issue	Desire changed when another medication started, or sex is painful

Wisp PT-141 nasal spray vs. Vyleesi at a glance

Decision fact	Wisp Bremelanotide (PT-141) Nasal Solution	Vyleesi
Regulatory status	Compounded; not FDA-approved	FDA-approved bremelanotide injection
Route	Nasal spray	Subcutaneous autoinjector
Public dose information	Wisp says one to two sprays, but does not publish milligrams per spray in the rendered page	1.75 mg in 0.3 mL per single-dose autoinjector
Public price	Starting at $175; one-time or subscription	Manufacturer program says most commercially insured patients pay $0; four doses are $99 without coverage, subject to eligibility and terms
Quantity published	Not in the publicly rendered product page	Four-dose box in the manufacturer offer
Cost per intended use	Cannot be calculated from public information	$0 for eligible patients or $24.75 per dose at the $99 four-dose price
FDA-labeled population	None; the compounded nasal preparation is unapproved	Premenopausal women with acquired, generalized HSDD that is not due to another condition, relationship problems, or a medication
Use ceiling	Wisp does not publish a product-specific ceiling in the rendered page	No more than one dose in 24 hours; more than eight doses per month is not recommended
If it does not help	Wisp's terms make product sales final except for narrow fulfillment problems	The label says to stop after eight weeks if symptoms do not improve

How to read this page: Verified means we checked a dated primary or direct commercial source. Provider-stated means the company publishes the claim. Not publicly disclosed means we checked the rendered pages named in the methodology section and did not find the detail. Confirm before payment means the information may appear only during intake, clinician review, checkout, or on the pharmacy label.

Do not try to calculate around a missing denominator. Jump to the seven questions to ask before you pay.

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

What is Wisp actually selling?

Wisp sells a prescription product called Bremelanotide (PT-141) Nasal Solution, starting at $175, with a one-time-purchase or subscription option. Its page says to use one to two sprays 45 to 60 minutes before intimacy and calls the product compounded. The rendered page does not disclose the concentration, milligrams delivered per spray, bottle volume, spray count, beyond-use date, or dispensing pharmacy.^[1]

That is what is plainly there. Here is what it means.

Bremelanotide is a synthetic peptide and melanocortin-receptor agonist. Wisp markets its nasal preparation as acting on brain pathways involved in desire rather than directly on peripheral blood flow. The FDA-approved Vyleesi label also identifies melanocortin-receptor activity, but says the mechanism by which Vyleesi improves HSDD is unknown.^[10] That is the clean line between marketing language and a regulated label.

Wisp places PT-141 in “Longevity & Healthy Aging”

The placement is unusual enough to matter. Wisp files PT-141 under its Longevity & Healthy Aging category rather than menopause or a dedicated female sexual-health category. We recorded the public price ladder on August 13, 2026:^[2]

Do not confuse this $175 nasal product with Wisp's separate menopause-consult pathway, which has a different price structure and medication model. See our Wisp menopause cost review for that service.

Wisp longevity product	Price displayed
Low-Dose Naltrexone Capsules	Starting at $75
GHK-Cu Topical Cream (0.5%)	Starting at $102.50
Glutathione Injection	Starting at $125/month
Tru Niagen 300 mg	$127
Glutathione Nasal Spray	Starting at $130
NAD+ Nasal Spray	Starting at $150
Bremelanotide (PT-141) Nasal Solution	Starting at $175
NAD+ Injections	$25 consultation

Three things fall out of that table.

One: PT-141 is the most expensive nasal spray displayed in that category. It is $175, compared with $150 for NAD+ and $130 for glutathione.

Two: the subscription cadence still cannot be inferred. Wisp displays $175 without a monthly unit and separately offers a subscription. That does not tell you whether $175 is charged monthly, at a different refill interval, or only when a prescription refill is processed. We are not going to invent an annual price from formatting.

Three: Wisp sells low-dose naltrexone on the same longevity page. That becomes relevant later because the Vyleesi label contains a specific oral-naltrexone interaction warning. The warning belongs to the approved injection label and cannot automatically be transferred to Wisp's nasal preparation, but naltrexone still belongs on the medication list you give the prescriber.

Wisp is not the dispensing pharmacy

Wisp's terms say it does not manufacture the products offered through its service. Its process connects a customer with an independent medical provider, and a prescription may then be sent to a mail-order or local pharmacy if the prescriber finds treatment appropriate.^[3]

That is a legitimate telehealth model. It also means the pharmacy identity matters. We could not find the dispensing pharmacy named in the publicly rendered PT-141 page. It may be disclosed during intake, checkout, fulfillment, or on the label. Ask before paying.

Is Wisp legitimate, or is it a scam?

Wisp is a real operating telehealth company, not an anonymous “research peptide” seller. BBB lists the business as having started in 2018, and Wisp's terms require a medical consultation and an independent prescriber's decision before a prescription product is dispensed.^[22][3]

That answers the company question. It does not answer the product question.

“Real company” and “FDA-approved product” are different claims. Wisp clears the first bar. This compounded nasal preparation does not clear the second, and Wisp's own page includes an FDA-status disclosure in its footer.^[1]

The three review numbers do not measure the same thing

Source	Public snapshot	What it can tell you	What it cannot tell you
Wisp product page	4.3/5 company-review widget	The rating Wisp displays on the sales page	Product-level PT-141 outcomes
Trustpilot	4.0/5 from 11,395 reviews	Broad service experience across Wisp's catalog	Whether this nasal formula works or what is in the bottle
Better Business Bureau	Not accredited; D−; reason shown as failure to respond to 14 complaints	A current customer-service and complaint-response signal	Clinical quality or product efficacy

The 4.3-versus-4.0 difference is not evidence of fraud. An embedded widget can lag or use a different refresh point. The responsible move is to label each number with its source and date instead of averaging them into a fake score.

The BBB result is a service warning, not a medical finding. It matters here because the purchase can be non-refundable and subscriptions require advance cancellation. It does not prove anything about bremelanotide's effects.

And none of these ratings is a Wisp PT-141 review pool. They cover Wisp's wider service, including unrelated treatments.

What is the one number Wisp does not publish — and why does it decide everything?

The decisive missing detail is dose per spray, usually stated directly in milligrams per spray or derived from concentration and metered spray volume. Wisp publicly says “one to two sprays,” but a spray count is not a drug amount. Without the dose and bottle quantity, you cannot calculate cost per intended use or place Wisp's preparation beside the published nasal research.

This is the heart of the review.

A metered nasal actuator dispenses a volume. The amount of medication delivered depends on the formulation concentration and the volume delivered with each actuation. The cleanest consumer disclosure is simply mg per spray. Wisp does not publish that figure in the rendered page we reviewed.

The nasal evidence ladder

Source	Population and setting	Route and dose	What was reported
Diamond et al., Journal of Sexual Medicine (2006)	18 premenopausal women with female sexual arousal disorder; randomized crossover, in clinic	Intranasal, single 20 mg dose	More women reported moderate or high desire than with placebo; satisfaction with arousal improved among women who attempted intercourse; genital-arousal feelings did not reach statistical significance, and vaginal vasocongestion did not change significantly. The authors called it preliminary.[13]
Clayton et al., Clinical Therapeutics (2017)	24 healthy adults; supervised Phase 1 study with and without ethanol	Intranasal, 20 mg on three study days	The study reported that the regimen was generally well tolerated in this small, controlled setting, with no discontinuations due to adverse events.[14]
Palatin patent, Example 2	76 premenopausal women with female sexual arousal disorder; 40 received drug in an at-home study	Intranasal, 10 mg	22 of 40 completed; 16 of 40, or 40%, discontinued because of an adverse event. The patent reported much wider peak-concentration variability than in its 1.75 mg subcutaneous example and linked that variability to adverse events and reduced efficacy.[15]
Vyleesi prescribing information	Premenopausal women with acquired, generalized HSDD	Subcutaneous, 1.75 mg	Standardized approved dose, pharmacokinetics, contraindications, adverse-event rates, and use limits are published in the label.[10]
Wisp	Adults Wisp markets to; product-specific study not published	Nasal; one to two sprays	Concentration and milligrams per spray are not publicly disclosed in the rendered page.[1]

These rows are not interchangeable. A 10 mg or 20 mg research dose does not tell you what Wisp prescribes, and Vyleesi's 1.75 mg injected dose does not provide a conversion formula for an undisclosed nasal preparation.

The useful conclusion is narrower and stronger: Wisp's public information does not let you put its product anywhere on the ladder. Unknown does not mean weak. It does not mean strong. It means unknown.

Other sellers prove that this disclosure is possible

This is not a standard no one can meet. We checked public product information from several sellers and assembled the same fields across them:

Seller or product	Public price	Public strength or dose	Public quantity	Can a consumer calculate cost per intended use?
Wisp PT-141 nasal solution	Starting at $175	No mg/mL or mg/spray in rendered page	No bottle volume or spray count in rendered page	No
Hone PT-141 spray	Price not stated in the help article	1 mg per spray; maximum 2 mg per use	10 sprays per 28-day supply	Dose count is clear; price is missing from that source
PHC Pharmacy nasal spray	$125	5 mg/mL	10 mL bottle	Not fully; the metered volume or mg per spray is not stated
AgeMD PT-141 nasal program	$224/month for 3 months, $204/month for 6 months, or $187/month billed annually	No public mg-per-spray figure found	No public spray count found	No
beyondMD PT-141 nasal program	Starting at $384	No public mg-per-spray figure found	No public spray count found	No
Vyleesi manufacturer program	$0 for many eligible commercially insured patients; $99 if not covered	1.75 mg per autoinjector	Four-dose box	Yes

Hone publishes the consumer-facing number Wisp is missing: 1 mg per spray, plus a 10-spray supply and storage window.^[17] PHC publishes concentration, bottle volume, storage, and price, although it still does not publish the metered amount delivered per spray.^[18] AgeMD and beyondMD illustrate another pricing problem: a displayed monthly or starting price still does not create cost-per-use transparency without dose and quantity.^[19][20]

The seven questions to ask before you pay

Copy and paste this into Wisp's care chat before checkout:

I'm considering the Bremelanotide (PT-141) Nasal Solution and want to understand the exact prescription before paying. Please confirm:

1. What is the concentration in mg/mL?
2. How many milligrams does one spray deliver?
3. Does “one to two sprays” mean one to two sprays total or one to two per nostril?
4. What is the bottle volume, total metered spray count, and expected number of prescribed uses?
5. Which pharmacy compounds and dispenses it, and is the facility operating as a 503A pharmacy or a registered 503B outsourcing facility for this order?
6. What are the storage instructions and beyond-use date on the dispensed label?
7. If I choose a subscription, what is the refill interval, the next charge date, and the deadline to cancel that charge?

Add one more question if it applies: “I take or am considering oral naltrexone. Does that change whether this prescription is appropriate?”

Once Wisp gives you the quantity, the math is simple:

Cost per prescribed use = total amount charged ÷ number of prescribed uses in the bottle

Until both numbers are known, any cost-per-dose claim is invented.

Is Wisp PT-141 nasal spray FDA-approved?

No. Wisp describes its PT-141 nasal solution as compounded. Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before marketing.^[6]

Bremelanotide has one FDA-approved product: Vyleesi, a 1.75 mg subcutaneous injection for premenopausal women with acquired, generalized HSDD that causes marked distress or interpersonal difficulty and is not due to another condition, relationship problems, or medication effects.^[10]

That does not make Wisp's nasal preparation an approved “version” of Vyleesi. FDA approves specific products, formulations, routes, doses, and indications. The agency has explicitly warned telehealth companies not to describe compounded drugs as generic, the same as an approved drug, or clinically proven to produce the same results.^[7]

“Off-label” and “compounded” are not the same category

Wisp's footer says the specific use is not FDA-approved and describes it as off-label. That is more disclosure than many sellers provide, but the terminology needs separating.

• Off-label prescribing uses an FDA-approved product outside its approved labeling. The approved product still has a label with strength, manufacturing standards, pharmacokinetics, contraindications, and adverse-event data.
• A compounded preparation is not FDA-approved. It does not have an FDA-approved label for the bottle being dispensed.

A clinician may prescribe a compounded drug when legally and medically appropriate. But calling the preparation itself “off-label” can make the missing product-level review sound smaller than it is. The practical consequence is exactly what you see here: there is no FDA label that tells you what Wisp's bottle contains.

Wisp's own page changes temperature as you scroll

Page location	Wisp's wording
Main description	The spray “promotes the source of sexual desire” and says the formula works at the neurological level
Product explanation	It “helps support sexual desire”
Mechanism section	It is “sometimes called a desire switch”
Footer	The safety and effectiveness of medications for the described unapproved use may not be established by FDA

The claim gets cooler as the regulatory disclosure gets closer. That does not prove the product does not work. It tells you which sentences are marketing and which sentence carries the legal reality.

And one piece of honesty cuts both ways: unapproved does not automatically mean harmful, ineffective, gentler, stronger, or more natural. It means FDA has not evaluated this compounded product before marketing.

Before spending $175, check the approved route you may qualify for. See Vyleesi's official price and eligibility information. We earn nothing from that link.

What does Wisp PT-141 cost, and what does $175 actually buy?

Wisp displays a starting price of $175 and offers a one-time purchase or subscription. The public page does not state what quantity that price buys, so neither cost per use nor annual cost can be calculated.^[1]

Here is the only comparison that does not require guesswork:

Path	Public amount charged	Public quantity	Cost per use
Vyleesi manufacturer pathway, eligible commercial insurance	Often $0, subject to terms	Four doses	$0
Vyleesi manufacturer pathway, no coverage	$99, subject to terms	Four doses	$24.75
Wisp PT-141 nasal solution	Starting at $175	Not publicly disclosed	Cannot be calculated
PHC Pharmacy nasal listing	$125	10 mL, but spray delivery and prescribed use count not stated	Cannot be calculated reliably
AgeMD nasal program	$224/month quarterly; $204/month semiannually; $187/month annually	Public dose count not found	Cannot be calculated
beyondMD nasal program	Starting at $384	Public dose count not found	Cannot be calculated

The Vyleesi manufacturer offer is not universal insurance coverage. Eligibility rules apply, government-funded coverage is excluded from manufacturer savings, and the program can change. The point is not that everyone pays $0. The point is that the official pathway publishes a four-dose quantity and an eligibility-dependent price, so the denominator exists.^[11]

If a page compares a compounded spray with a four-figure retail estimate for Vyleesi but never checks the manufacturer's current program, the comparison is incomplete. Before trusting any price comparison — including ours — check the manufacturer's page on the day you act.

What is not publicly itemized in the $175 price

Wisp's rendered product page does not identify:

• The milligrams per spray
• The bottle volume or total spray count
• The expected number of prescribed uses
• The dispensing pharmacy
• The beyond-use date and storage conditions
• Any included laboratory testing
• The subscription refill interval

That does not prove none of these details appears later. It means they are not available in the public product information we could verify. The clinician, checkout flow, pharmacy label, or patient portal may provide them. Get the answer before the charge becomes final.

Does nasal bremelanotide actually work?

There is human research on intranasal bremelanotide, but it does not establish that Wisp's undisclosed formulation is effective. The published and patent-described studies used specific research doses, in small or older studies, and produced a mixed picture. No head-to-head study compares Wisp's nasal solution with Vyleesi, Addyi, placebo, or another compounded spray.

Diamond 2006: a small preliminary signal

Eighteen premenopausal women with female sexual arousal disorder received a single 20 mg intranasal dose and placebo in a randomized crossover design. Subjective desire improved, and women who attempted intercourse were more satisfied with their arousal after bremelanotide. Feelings of genital arousal showed a non-significant trend, and the objective vaginal-vasocongestion measure did not change significantly.^[13]

That is not nothing. It is also an 18-person preliminary study using a 20 mg research dose — not evidence about Wisp's bottle.

Clayton 2017: reassuring inside a small supervised study

A Phase 1 study exposed 24 healthy adults to 20 mg intranasal bremelanotide on three study days with and without ethanol. The published report described the treatment as generally well tolerated and reported no discontinuations because of adverse events.^[14]

That is a favorable nasal data point. It is also a short, supervised safety study in healthy volunteers, not an effectiveness trial of a commercial compounded product.

The Palatin patent: the at-home result that changes the picture

A Palatin patent describes an at-home study in 76 premenopausal women with female sexual arousal disorder. Forty received a 10 mg intranasal dose. Twenty-two completed, while 16 of 40 — 40% — discontinued because of an adverse event. The same example reported a peak-concentration coefficient of variation of 58.6% for the nasal group versus 25% in a separate 1.75 mg subcutaneous example, with nasal values ranging from zero to 207 ng/mL at 30 minutes.^[15]

This is patent text, not a peer-reviewed journal article, and it should be labeled that way. It is still primary historical documentation from the developer's program.

Why the developer moved away from the nasal route

Palatin later stated that blood-pressure increases in some patients, combined with significant variation in plasma levels, led it to discontinue nasally administered bremelanotide as a first-line therapy for sexual dysfunction.^[16]

The variation matters as much as the blood pressure. A route that produces wide swings in exposure makes dosing less predictable. That historical problem does not prove Wisp's current preparation repeats the same result. It is the reason an undisclosed strength and dose should not be waved away as a minor labeling gap.

The “desire switch” is marketing, not a settled mechanism

Wisp calls PT-141 a “desire switch.” The Vyleesi label says bremelanotide activates melanocortin receptors and then states that the mechanism by which Vyleesi improves HSDD is unknown.^[10]

That is not a gotcha. It is the difference between a memorable sales phrase and what the approved label can support.

The honest bottom line: there is no efficacy winner to declare for Wisp's formula. Anyone claiming it is equivalent, superior, or predictably gentler than an FDA-approved option is going beyond the evidence.

Are you treating desire, arousal, orgasm, pain, or a medication effect?

Low desire is not one single problem. A medicine aimed at desire will not fix every cause of less interest in sex, and it will not directly treat painful penetration, vaginal dryness, or a medication side effect. Sorting the symptom correctly can save the entire $175.

What you notice	What it may point toward	Better first question
Almost no interest, and the loss itself causes distress	A desire-focused assessment, including whether the pattern meets acquired, generalized HSDD criteria	“Does my pattern fit HSDD, and what else could be driving it?”
You want sex, but your body does not respond as expected	Arousal, blood-flow, sensation, medication, or pelvic-health factors	“Is this desire, arousal, or both?”
Sex is dry, burning, tight, or painful	Genitourinary syndrome of menopause, another vulvovaginal condition, pelvic-floor dysfunction, infection, or another cause of pain	“Should the pain and dryness be evaluated first?”
Desire changed when an SSRI, blood-pressure medicine, hormonal contraceptive, or another drug started	A medication effect	“Could the timing point to the medication?”
Hot flashes, broken sleep, mood disruption, and low desire arrived together	Menopause symptoms affecting energy, comfort, sleep, or wellbeing	“Is low desire the primary problem or part of a larger symptom cluster?”
Interest changes sharply with stress, safety, conflict, or relationship context	A broader biopsychosocial issue	“Would medication address the part that is actually causing distress?”

Both the Vyleesi and Addyi labels define their HSDD indications as low desire that is not due to another medication, another medical or psychiatric condition, or relationship problems.^[10][12]

For the wider symptom and treatment map, see our menopause libido and sexual-health guide.

If sex hurts, do not ask a desire drug to solve a pain problem. Pain and dryness deserve their own evaluation. For menopause-related vaginal symptoms, start with our vaginal estrogen and local-treatment guides rather than forcing a libido product into the wrong job.

Not sure which row is yours? Use Find My HRT Path to get a situation-based starting point and a flag when online care is not the right first stop.

What changes if you have gone through menopause?

The life-stage fork changes the approved options. Vyleesi is not indicated for postmenopausal women. The current Addyi label, revised in December 2025, covers women under 65 with acquired, generalized HSDD regardless of menopausal status.^[10][12]

Situation	FDA-approved HSDD option to ask about	Main trade-off
Premenopausal, acquired generalized HSDD	Vyleesi 1.75 mg injection as needed, or Addyi 100 mg daily at bedtime	Vyleesi uses a needle and commonly causes nausea; Addyi is daily and carries hypotension, syncope, CNS-depression, alcohol-timing, interaction, and liver-impairment restrictions
Postmenopausal and under 65, acquired generalized HSDD	Addyi 100 mg daily at bedtime	Daily dosing; stop after eight weeks if there is no improvement; safety restrictions matter
Age 65 or older	Neither Vyleesi nor Addyi has a labeled indication for this group	A clinician needs to evaluate causes and options without pretending a label covers you
Low desire due to another medicine, condition, or relationship problem	Neither labeled HSDD indication fits that cause	Review and address the driver first

The Addyi update most older comparison pages miss

The Addyi prescribing information lists a December 2025 indication change and now says the drug is indicated for women less than 65 years of age with acquired, generalized HSDD. In Study 6, 447 postmenopausal women under 65 received Addyi and 455 received placebo.^[12]

The downsides are real. Across the two postmenopausal trials summarized in the label, adverse reactions led to discontinuation in 9% of Addyi-treated women versus 5% with placebo. Common postmenopausal-trial adverse reactions included dizziness, somnolence, nausea, fatigue, insomnia, and dry mouth. The label also carries a boxed warning for severe hypotension and syncope in certain settings, including alcohol use close in time, moderate or strong CYP3A4 inhibitors, and hepatic impairment.^[12]

That is a serious trade-off against an as-needed nasal spray. It is also a standardized FDA-approved tablet with a public label, not a mystery bottle.

So here is the fork in plain English:

If you are postmenopausal and under 65 and your pattern fits acquired, generalized HSDD, the FDA-approved conversation is now about Addyi — not nasal bremelanotide.

That does not mean Addyi is right for you. It means a current review should tell you the option exists before sending you to a compounded peptide checkout.

What side effects and interactions matter most?

Three evidence buckets must stay separate: the Vyleesi label, historical nasal-program findings, and what is unknown about Wisp's specific preparation. Mixing them creates fake certainty.

1. What the Vyleesi label reports

These figures describe the 1.75 mg subcutaneous FDA-approved product, not Wisp's nasal spray:^[10]

• Nausea occurred in 40% of patients in the Phase 3 trials; 13% received anti-nausea medication and 8% discontinued because of nausea.
• Nausea was most common after the first dose and improved for most patients with the second dose.
• Other common adverse reactions included flushing, injection-site reactions, headache, and vomiting.
• Vyleesi is contraindicated in uncontrolled hypertension and known cardiovascular disease.
• Focal hyperpigmentation occurred in about 1% of patients, and resolution was not confirmed in every patient after stopping.
• The label recommends no more than one dose in 24 hours and says more than eight doses per month is not recommended.
• The label warns of potential fetal harm, advises effective contraception, and says to discontinue if pregnancy is suspected.

Do not transfer those percentages to Wisp in either direction. An unknown nasal dose could produce a different profile, and there is no Wisp-specific trial that supplies the missing numbers.

2. What the historical nasal program reported

Palatin cited blood-pressure increases in some patients and significant variation in plasma levels when it explained why the nasal route was discontinued as a first-line development path.^[16] The patent-described at-home study also linked wider exposure variability to adverse events.^[15]

Those findings justify caution and better disclosure. They do not prove that every compounded nasal formulation produces the same rate or severity of events.

3. What remains unknown for Wisp

The public page does not provide product-specific rates for nausea, blood-pressure changes, nasal irritation, congestion, headache, flushing, skin darkening, or discontinuation. The collapsed side-effects section was not present in the rendered content available to us. Ask for the actual patient information and pharmacy label before use.

Wisp also says PT-141 is “safe to pair” with its compounded OMG! Cream.^[1] The page does not show product-specific clinical or interaction data supporting that combination, and the public PT-141 dose is missing. Treat that sentence as a provider-stated claim, not an independently verified safety conclusion, and put both prescriptions on the intake.

The naltrexone issue on Wisp's own category page

The Vyleesi label says bremelanotide can slow gastric emptying and may significantly reduce exposure to oral naltrexone. It says to avoid Vyleesi with oral naltrexone products intended to treat alcohol or opioid addiction because treatment failure could have severe consequences.^[10]

Wisp also sells low-dose naltrexone capsules on the same longevity page as PT-141.^[2]

This is not an allegation that Wisp is dispensing an unsafe combination. Low-dose naltrexone is used in a different context, and the label's strongest avoidance language is specifically tied to addiction treatment. The Wisp nasal product also lacks public pharmacokinetic data, so the magnitude of any interaction cannot be assumed from Vyleesi.

But the intake question is obvious: if you take oral naltrexone for any reason, put it in writing before the prescriber reviews PT-141.

When this belongs outside a checkout flow

Uncontrolled blood pressure, known cardiovascular disease, pregnancy or trying to conceive, fainting, chest pain, a severe or unusual headache, or a new significant symptom after a dose deserves direct clinical attention. Chest pain, fainting, signs of stroke, or another possible emergency belongs with emergency services, not customer support.

Is compounded PT-141 legal, and is it a controlled substance?

A compounded bremelanotide prescription may have a lawful pathway, but a public product page is not enough to declare that any specific bottle complies with every federal and state requirement. The product is not FDA-approved, the dispensing pharmacy is not publicly identified on Wisp's rendered page, and 503A and 503B impose different conditions.^[6]

For a traditional 503A prescription, federal law allows certain bulk substances when specified conditions are met, including a substance that is a component of an FDA-approved drug. Bremelanotide is a component of Vyleesi. That fact alone does not prove a particular prescription, pharmacy, formulation, or volume complies with all compounding rules.

Federal law also restricts compounding products that are essentially copies of commercially available approved drugs. FDA's guidance considers factors including the active ingredient, strength, and route of administration.^[9] Wisp's nasal route differs from Vyleesi's subcutaneous route, so the public facts do not support a simple “illegal copy” accusation. They also do not support a blanket legality verdict.

The honest questions are practical:

• Which pharmacy is dispensing this order?
• Is it a state-licensed 503A pharmacy or a registered 503B outsourcing facility for the relevant activity?
• What patient-specific prescription and state rules apply?
• What product label and adverse-event contact will arrive with the medication?

The 2026 peptide lists do not approve Wisp's product

Bremelanotide does not appear on FDA's May 14, 2026 Category 2 list of 503A bulk substances that raise significant safety risks.^[8] That is useful context, but absence from Category 2 is not FDA approval, proof of quality, or a finding that Wisp's nasal formulation is safe or effective.

Is PT-141 federally controlled?

Bremelanotide does not appear in DEA's June 25, 2026 alphabetical list of federally controlled substances. It is not federally scheduled like testosterone, which is Schedule III.^[23] Wisp still sells PT-141 as a prescription product requiring prescriber review. “Not controlled” does not mean “over the counter” or “self-dose from a research vial.”

Does Wisp accept insurance, HSA/FSA, and ship to my state?

Wisp displays PT-141 as a direct online purchase starting at $175. We found no product-specific statement on the rendered page saying that Wisp bills insurance for the mailed compounded nasal product. Treat the displayed amount as cash-pay unless Wisp confirms otherwise before checkout.

HSA and FSA

Wisp's general pricing page says most products can be purchased with HSA or FSA funds.^[5] It does not identify PT-141 by name in that statement. Card acceptance also does not guarantee your plan administrator will approve the expense. Confirm product eligibility with Wisp and your plan rather than treating “most products” as a promise about this one.

Shipping

Wisp's shipping policy says delivery generally takes three to five business days and expedited shipping is not offered. Its general pricing page says products ship free to all 50 states.^[4][5]

That still does not prove this specific prescription can be written and compounded for a patient in every state. The PT-141 page contains a product-category state-eligibility question, but the answer was not available in the rendered content we reviewed.

Ask first: “Is this specific prescription available in my state today, and which pharmacy will dispense it?”

Prescription speed is not package speed

Wisp says most prescriptions are sent to the pharmacy within three hours after the medical intake and any required call or video chat. That is the prescription handoff, not delivery to your door. Do not turn a pharmacy-routing statistic into a same-day shipping promise.^[4]

What happens to your $175 if it does not work?

Wisp's current terms say product sales are final except for four narrow situations: the product is out of stock, a prescription product is unavailable at local pharmacies, the product arrives damaged or defective, or the customer does not receive it. Refunds outside those cases remain at Wisp's discretion.^[3]

“It did not work for me” is not one of the listed exceptions. That is common with dispensed prescription products, which generally cannot be returned for resale. It is still a material buying fact when the public page does not disclose how many uses the $175 buys.

The subscription deadline

Wisp's terms require cancellation at least 48 hours before the next refill or renewal period to avoid the next charge. Cancellation can be submitted through the patient portal or by contacting support.^[3]

Turn that into a calendar action:

1. Screenshot the total, refill interval, and next charge date before confirming the order.
2. Set a reminder 72 hours before the renewal date, not 48, so you have a buffer.
3. Save the cancellation confirmation and timestamp.
4. If the product arrives without the disclosed strength, pharmacy name, directions, storage conditions, or beyond-use date you were promised, contact the prescriber and pharmacy before using it.

The current BBB rating and a visible Trustpilot cancellation complaint make that reminder more than housekeeping. They are service signals, not proof that every cancellation fails, but ignoring them would not help the reader.^[21][22]

The problem with what we are recommending instead

We have been telling you to check FDA-approved options first. So here is the damaging admission without the polished sales version.

For an eligible premenopausal woman, Vyleesi is a needle. It is a shot in the abdomen or thigh at least 45 minutes before anticipated sexual activity. Its label reports nausea in 40% of patients, 13% needed anti-nausea medication, and 8% stopped because of nausea.^[10]

If needles are the entire reason you found Wisp, that objection is not irrational. A nasal spray is easier to imagine using. It is discreet. It avoids an injection. The approved route asks something real of you.

The nausea is also front-loaded. The manufacturer reports nausea in 21% after the first dose, 3% after the second, and 2% after the third.^[11] That does not guarantee your experience, and it does not erase the 40% cumulative trial figure. It gives you a more complete picture for the prescriber conversation.

What the injection buys you is not glamour. It buys you a dose printed on the box, an FDA-reviewed label, a defined monthly ceiling, and a manufacturer price with a known four-dose denominator.

And if you are postmenopausal and under 65 with acquired, generalized HSDD, the current approved conversation is not a needle at all. It is Addyi, a daily pill with its own serious drawbacks and a public label.

If you weigh all of that and still prefer the needle-free compounded route, that is a decision you can discuss with a prescriber. Do not let anyone turn “needle-free” into permission to buy blind. Get the seven answers in writing first.

Does the needle-free trade-off still fit after you know what is missing? See Wisp's current PT-141 page, then ask the seven questions before paying. We earn nothing from that link.

What does this Wisp PT-141 nasal spray review find in customer reviews?

We found no verifiable public product-level review pool for Wisp's PT-141 nasal spray. Wisp's page displays a company-level Trustpilot score, and Trustpilot's live profile covers the entire Wisp service. Neither isolates people who received this nasal product, what concentration they received, or whether their symptoms matched HSDD.^[1][21]

That absence is a finding. We are publishing it instead of inventing a star rating.

Two current Trustpilot examples show what company-level reviews can and cannot do:

“Simple and easy.” — Leah, Trustpilot. A service and consultation review, not a PT-141 outcome review.^[21]

“I KEEP receiving it.” — Mary Neal, Trustpilot. A subscription-cancellation complaint; the medication was not identified as PT-141.^[21]

Those reviews can tell you that some customers find the intake smooth and that at least one customer reported refill-cancellation trouble. They cannot tell you the strength of Wisp's spray or establish safety or effectiveness.

Wisp also publishes a clinician quote saying the product is “worth a try.” The clinician's credential may be real; the quote is still seller copy, not product-specific clinical evidence.

A review can tell you whether a company answered an email. It cannot tell you what is in an undisclosed bottle. That is a documents question.

What should you do instead, based on your situation?

The next step depends on life stage, the actual symptom, insurance, risk history, and whether a needle is a barrier or simply an unpleasant surprise.

If this sounds like you	Do this first
Premenopausal with acquired, generalized low desire that causes distress	Check the current Vyleesi and Addyi labels and discuss which labeled option, if either, fits your history before paying for a compounded spray
Postmenopausal and under 65 with acquired, generalized HSDD	Ask about Addyi's current indication, alcohol timing, drug interactions, liver restriction, daily dosing, and eight-week stop rule
Age 65 or older	Neither label covers this group; start with a clinician who can evaluate the full cause and options
Sex is painful, dry, burning, or tight	Evaluate pain and genitourinary symptoms first; a desire drug may be the wrong tool
Desire changed when another medication started	Review the medication and timing with the prescriber who manages it
Already on menopause hormone therapy but low desire persists	Ask for a broader sexual-health assessment rather than assuming more estrogen or a peptide is automatically the answer
Needles are non-negotiable and you still want Wisp	Ask all seven questions, confirm your state and pharmacy, and do not pay without the dose and quantity
Not sure which problem you are solving	Use Find My HRT Path before choosing a provider or medication route

We deliberately did not route you to another compounded affiliate product as the automatic alternative. A page built around missing strength and quantity cannot excuse the same disclosure gap because another seller pays a commission.

Do not replace telehealth with a “research use only” marketplace

Searches for PT-141 bring up low-cost vials and sprays sold without a prescriber or identifiable dispensing pharmacy. A label saying “research use only” is not a prescription, not proof of identity or purity, and not an FDA-approved medicine for human use.

Wisp's prescriber review is a meaningful advantage over that market. But Wisp is not the pharmacy, and an unnamed pharmacy is not the ceiling for transparency. A licensed prescriber and an identifiable licensed dispenser are the floor.

What would change our verdict?

This review reaches a conditional conclusion based on the information Wisp publishes now. Three things would materially change it:

1. Wisp publishes the concentration, milligrams per spray, bottle volume, spray count, pharmacy, storage instructions, beyond-use date, and refill cadence. The cost-per-use comparison becomes possible and the central transparency criticism shrinks or disappears.
2. The Vyleesi manufacturer program changes. The current $0/$99 comparison is time-sensitive and must be rechecked before publication updates and before a reader acts.
3. Product-specific research appears for Wisp's disclosed nasal formulation. Evidence on a named concentration, dose, pharmacy-standardized preparation, and defined population would materially change the effectiveness and safety discussion.

We are committed to a method, not a permanent conclusion. If Wisp publishes the missing information, this page should be rewritten in its favor as quickly as it would be corrected against it.

Frequently asked questions

Is Wisp's PT-141 nasal spray FDA-approved?

No. Wisp calls it a compounded prescription nasal option. Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before marketing. Vyleesi is the FDA-approved bremelanotide product, and it is a 1.75 mg subcutaneous injection for a defined premenopausal HSDD population.

How much does Wisp PT-141 cost per dose?

It cannot be calculated from Wisp's public page. Wisp displays a starting price of $175 but does not publish the bottle volume, metered spray count, or number of prescribed uses. Ask for all three before paying.

How many sprays are in a Wisp bottle?

Wisp does not state the total spray count in the publicly rendered product page we reviewed on August 13, 2026. The amount may appear during intake, checkout, or on the pharmacy label; confirm it before the sale becomes final.

Does “one to two sprays” mean total or per nostril?

The rendered page does not say. That ambiguity can double the number of actuations, so ask the prescriber to write the total dose in milligrams and the exact nostril instructions.

Is Wisp PT-141 safe?

There is no public Wisp-specific study or disclosed dose from which to calculate a product-specific adverse-event rate. The Vyleesi label and historical nasal studies provide relevant questions, not transferable percentages. Safety depends on the actual formulation, dose, medical history, medications, and prescriber assessment.

Does PT-141 work for postmenopausal women?

Vyleesi is not indicated for postmenopausal women. The current Addyi label covers women under 65 with acquired, generalized HSDD, including postmenopausal women. That does not establish that Wisp's compounded nasal product works for postmenopausal women.

How long does Wisp PT-141 take to work?

Wisp says to use one to two sprays 45 to 60 minutes before intimacy. That is provider instruction, not evidence that every user will respond in that window. Follow the prescription label rather than changing the timing or dose yourself.

Can I use Wisp PT-141 with HRT?

That requires a prescriber review of the full medication list and medical history. Include systemic hormone therapy, vaginal treatments, antidepressants, blood-pressure medication, alcohol or opioid-use treatment, oral naltrexone, supplements, and pregnancy plans. Do not assume “non-hormonal” means interaction-free.

Can I get a refund if it does not work?

Wisp's terms make product sales final except for narrow stock, local-pharmacy availability, damage or defect, and non-delivery situations. Lack of effect is not listed as a refund reason.

Is compounded PT-141 legal in 2026?

There can be a lawful compounding pathway, but legality depends on the pharmacy, prescription, state, formulation, and compliance with 503A or 503B conditions. Wisp's public page does not identify enough of those facts for this review to issue a bottle-specific legal verdict.

Is PT-141 a controlled substance?

Bremelanotide is not listed in DEA's June 25, 2026 alphabetical controlled-substance list and is not federally scheduled like testosterone. Wisp still requires a prescription and clinician review.

Is Wisp's spray as good as Vyleesi?

There is no evidence to answer that. No head-to-head trial exists, and Wisp does not publish its dose or product-specific outcomes. The correct answer is not “yes,” “no,” or “probably.” It is not established.

What should I ask before paying?

Ask for your state eligibility, concentration, milligrams per spray, total-versus-per-nostril instructions, bottle volume and spray count, dispensing pharmacy, storage and beyond-use date, subscription refill interval, next charge date, and cancellation deadline. Put naltrexone in the message if you take it.

The bottom line

Wisp's PT-141 nasal spray is a real prescription offer from an established telehealth company. It starts at $175, avoids a needle, and may be worth investigating for someone who understands the trade-off. But it is still a price without a publicly disclosed dose or quantity, and that is a genuine problem.

For an eligible premenopausal woman with acquired, generalized HSDD, check the official Vyleesi pathway before assuming the FDA-approved route costs four figures. For an eligible woman under 65 — including after menopause — check the current Addyi label rather than relying on older pages that still call it premenopausal-only.

If you still choose the needle-free compounded route, get the answers in writing. The goal is not to frighten you away from something you want. It is to make sure you know what you bought.

Still not sure which HRT program or starting point fits your situation? Take the free matching tool — it takes about 90 seconds.

→ Find My HRT Path

What we actually verified

On August 13, 2026, we checked Wisp's PT-141 product page, Longevity & Healthy Aging category, pricing page, shipping policy, and Terms of Service; the current Vyleesi prescribing information and manufacturer pricing page; the December 2025 Addyi prescribing information; FDA's current compounding guidance and Category 2 list; DEA's June 25, 2026 controlled-substance list; the Diamond 2006 and Clayton 2017 PubMed records; Palatin patent US9700592B2 and its nasal-route statement; public PT-141 information from Hone, PHC Pharmacy, AgeMD, and beyondMD; and current Wisp snapshots on Trustpilot and BBB.

What we could not verify and did not guess: Wisp's concentration, milligrams per spray, bottle volume, spray count, prescribed-use count, dispensing pharmacy, storage instructions, beyond-use date, product-specific state list, insurance treatment for the mailed compounded product, and subscription refill interval. We did not purchase the product or complete a medical intake.

How we review providers: This page follows The HRT Index Verification Standard. We read every published price, separate FDA-approved from compounded, verify state availability and insurance when the information is public, and re-check on a fixed schedule — top providers monthly and the full roster quarterly. We evaluate providers on five pillars, in this order: clinical legitimacy, care quality, medication fit, price transparency, and access. We do not assign numeric provider scores.

Corrections are part of the method. If Wisp publishes the missing details or a cited policy changes, this page should be updated and the verification date changed.

Sources

¹ Wisp — Bremelanotide (PT-141) Nasal Solution, accessed August 13, 2026.

² Wisp — Longevity & Healthy Aging, accessed August 13, 2026.

³ Wisp — Terms of Service, current version checked August 13, 2026.

⁴ Wisp — Shipping Policy, accessed August 13, 2026.

⁵ Wisp — Pricing, accessed August 13, 2026.

⁶ U.S. FDA — Compounding and the FDA: Questions and Answers, content current September 16, 2025; checked August 13, 2026.

⁷ U.S. FDA — What to Know When Promoting Compounded Drugs, June 15, 2026.

⁸ U.S. FDA — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A, updated May 14, 2026.

⁹ U.S. FDA — Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A, January 2018; checked August 13, 2026.

¹⁰ DailyMed — Vyleesi (bremelanotide injection) prescribing information, updated November 13, 2025; checked August 13, 2026.

¹¹ Vyleesi official site — savings, dosing, and safety information, checked August 13, 2026.

¹² DailyMed — Addyi (flibanserin) prescribing information, revised December 2025; checked August 13, 2026.

¹³ Diamond LE, et al. “An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141)”. Journal of Sexual Medicine. 2006;3(4):628–638. PMID 16839319.

¹⁴ Clayton AH, et al. “Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol”. Clinical Therapeutics. 2017;39(3):514–526.e14. PMID 28189361.

¹⁵ Palatin Technologies. US9700592B2 — Uses of bremelanotide in therapy for female sexual dysfunction, especially Example 2.

¹⁶ Palatin Technologies. Statement on discontinuation of nasally administered bremelanotide as a first-line therapy.

¹⁷ Hone Health — PT-141 (Bremelanotide) Spray, accessed August 13, 2026.

¹⁸ PHC Pharmacy — Bremelanotide (PT-141) Nasal Spray, 5 mg/mL, 10 mL, accessed August 13, 2026. Commercial specifications cited; promotional medical claims were not used as evidence.

¹⁹ AgeMD — PT-141 Nasal Spray, accessed August 13, 2026.

²⁰ beyondMD — PT-141 Nasal Spray Program, accessed August 13, 2026. Commercial price cited; promotional medical claims were not used as evidence.

²¹ Trustpilot — Wisp reviews, snapshot checked August 13, 2026. Company-level service reviews, not product efficacy evidence.

²² Better Business Bureau — Wisp Business Profile, checked August 13, 2026.

²³ DEA Diversion Control Division — Controlled Substances, Alphabetical Order, dated June 25, 2026.